Sinaptica Therapeutics has developed a personalized closed-loop neuromodulation therapy that utilizes rTMS-EEG to enhance neuroplasticity in key brain networks associated with memory in Alzheimer's patients. This therapy has demonstrated statistically significant slowing of disease progression, preserving cognitive function and reducing behavioral disturbances over a 12-month period in clinical trials.
Funding
Funding not disclosed
Founders
Product
Problem
Alzheimer's disease lacks effective treatments that can significantly slow cognitive decline and preserve function in affected individuals. Current therapeutic options offer limited symptomatic relief but do not address the underlying neurodegenerative processes.
Solution
Sinaptica Therapeutics is developing a personalized, closed-loop neuromodulation therapy designed to enhance neuroplasticity in key brain networks associated with memory, specifically targeting the Default Mode Network (DMN). The therapy utilizes repetitive transcranial magnetic stimulation (rTMS) guided by electroencephalography (EEG) to deliver individualized stimulation protocols. By calibrating stimulation based on MRI and TMS-Evoked potential (TEPs) measurements, the approach aims to optimize electrical stimulation of the precuneus, the central hub of the DMN. Clinical trial results indicate statistically significant slowing of Alzheimer's disease progression across cognitive, functional, and behavioral domains over a 12-month period.
Target Audience
The primary target audience includes individuals diagnosed with Alzheimer's disease and their caregivers, as well as neurologists and other healthcare professionals specializing in neurodegenerative disorders.
Features
- Personalized rTMS-EEG neuromodulation calibrated to individual brain activity and structure
- Neuronavigation for precise and repeatable stimulation of the precuneus
- Closed-loop system that adjusts stimulation parameters based on real-time EEG feedback
- Non-invasive delivery method
- Demonstrated slowing of disease progression in a randomized, double-blind, placebo-controlled Phase 2 clinical trial